Trump’s Drug Pricing Remarks: A Gambit For Industry Self-Restraint?
Comments during recent interview shows president-elect continues to view drug pricing as populist issue, revives speculation he may take action to control prices.
You may also be interested in...
Have pharma companies responded sufficiently to President Trump's call for “massive” price reductions?
Public Citizen reached out to the 28 largest biopharma manufacturers after Allergan announced its pricing pledge to see who else might follow suit. The answer was, not many.
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.